MBBS - R G Kar Medical College and Hospital - 2009 - Kolkata Verified
MD - Radiotherapy - West Bengal State University - 2013 - Kolkata Verified
DNB - Radiotherapy - National Board of Examinations - 2014 - Kolkata Verified
MNAMS Verified
Fellow of the Royal College of Radiologists - RCR - 2018 - London Verified
CESR - General Medical Council - UK Verified
Experiences
Specialist Registrar Leeds Cancer Centre - NHS Trust - UK - 2017 - 2018
Consultant Clinical Oncologist Leeds Cancer Centre - NHS Trust - UK - 2018 - 2019
Consultant Clinical Oncologist Apollo Multispeciality Hospital - Kankurgachi - 2019 - Currently Working
Registrations
64647 West Bengal Medical Council 2009 Verified
Awards and Recognitions
Certificate of Eligibility for Specialist Registration (CESR), UK Awarded by General Medical Council, UK in October - 2019
Cyclotron Trust Award with Travel Grant to Attend the Education Sessions of PTCOG-58 Conference held in Manchester , United Kingdom
Having Qualified for the Award of Diplomate of the National Board of Examinations in Radiotherapy at the Examination held in December, 2013; has been Admitted by the Council as Member (MNAMS) of the National Academy of Medical Sciences (India) in the year 2018
FRCR in Clinical Oncology Awarded by Royal College of Radiologists in April,2018
Achievements :
International training fellowship in St James University Hospital (Leeds teaching hospital), UK from March 2017- October 2018.
Fellowship in Clinical oncology from Tata Medical Center, Kolkata, India from June - 2013 to January - 2017
He was selected for ESMO preceptorship on Brain tumor held between September 28, 2018-September 29, 2018 in Athens, Greece.
Hypo-fractionated radiotherapy schedule of 35Gy in 10 Fractions in advanced incurable breast cancer: a prospective Phase I/II study (HYPORT study). He got first prize for poster presentation in controversies in Clinical Oncology, which was held in Kolkata, India in 2016
Oral Presentation in the Royal College of Radiologists Proffered Paper Session in NCRI Conference 2015, Liverpool, UK; for which He got ‘The Company of Biologists Travel Award’
‘Is Daily MVCT Imaging Really required in helical tomotherapy for head and neck cancers? : An analysis of a large dataset of 2858 fractions’. He had presented this research work in AROICON West Bengal chapter 2013 in Kolkata,India.
Memberships
Indian Medical Association (IMA)
Association of Radiation Oncologists of India (AROI)
National Academy of Medical Sciences
Indian Society of Neuro-Oncology (ISNO)
European Society of Medical Oncology (ESMO)
European Society for Radiotherapy & Oncology (ESTRO)
Indian Society of Oncology (ISO)
Royal College of Physicians (UK)
Paper Presentations
A Randomized, Double-Blind, Phase 3 Study of Pemetrexed + Platinum Chemotherapy with or without Pembrolizumab (MK-3475) in TKI-resistant EGFR-mutated Tumors in Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) Participants (KEYNOTE-789)
Addition of Stereotactic Body Radiotherapy to Systemic Chemotherapy in Locally Advanced Biliary Tract Cancers (ABC07 trial)
A Randomised Trial of Conventional Care Versus Radioablation (Stereotactic Body Radiotherapy) for Extracranial Oligometastases (CORE trial)
ETOP/IFCT 4-12 STIMULI Trial which is an Open-label, Randomised, Two-Arm, Phase II trial Looking into Addition of Immunotherapy with Nivolumab and Ipilumumab to Standard of Care in Limited Stage Small Cell Lung Carcinoma
A Randomized, Phase 3 Trial with Anti-PD-1 Monoclonal Antibody Pembrolizumab (MK-3475) Versus Placebo for Patients with Early Stage NSCLC after Resection and Completion of Standard Adjuvant Therapy (PEARLS)
GO40241 Phase III Randomized, Double-Blind, Placebo-Controlled Study (Neoadjuvant early stage resectable NSCLC) –Impower030 trial.
Stereotactic Ablative Radiotherapy for Oligometastatic Non-small Cell Lung Cancer: A Randomised Phase III Trial (SARON study)
A Multi-Centre Randomised Study of Induction Chemotherapy followed by Capecitabine(+/-nelfinavir) with High or Standard Dose Radiotherapy for Locally Advanced Nonmetastatic Pancreatic Cancer (SCALOP 2 study)
A Randomised Phase II trial of Standard Versus Dose Escalated Radiotherapy in the Treatment of Pain in Malignant Pleural Mesothelioma (SYSTEM 2 trial)
A Phase 2 Trial of Pembrolizumab (MK-3475) in Combination with Platinum Doublet Chemotherapy and Radiotherapy for Participants with Unresectable, Locally Advanced Stage III Non-Small Cell Lung Cancer (NSCLC) (KEYNOTE-799)
A Phase 3 Randomized, Placebo-controlled Study to Evaluate the Safety and Efficacy of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) with or without Lenvatinib (E7080/MK-7902) as First-line Intervention in Participants with Metastatic Nonsquamous Non-small Cell Lung Cancer (LEAP-006)
Adjuvant Durvalumab/placebo following SABR for stage I/II medically inoperable NSCLC (PACIFIC 4 study)
Adjuvant Durvalumab following Sequential Chemotherapy and Radiotherapy in Patients with Unresecatble Stage III NSCLC (PACIFIC 6 study)